Noxopharm Ltd. · ASX:NOX
Noxopharm — ASX Small-Mid Cap Conference 2021
24 slides from Noxopharm's conference presentation, Mar 16, 2021
Slide 1: ASX Announcement: ASX Small-Mid Cap Conference Corporate Presentation
For personal use only ASX Announcement | 16 March 2021 Noxopharm Limited (ASX:NOX) ASX Small-Mid Cap Conference Corporate Presentation Sydney 16 March 2021: Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) announces that CEO and Founder, Dr Graham Kelly, has been invite
Slide 2: Forward Looking Statements and Contacts
For personal use only STING signaling inhibition provides an anti-inflammatory effect, contributing to an anti-cancer action, but also potentially blocking sepsis; autophagy inhibition is believed to augment the immunotherapy effect of radiotherapy, in particular the triggering of an abscopal respon
Slide 3: ASX Small-Mid Cap Conference Presentation March 2021
For personal use only Noxopharm Limited (ASX:NOX) ASX SMALL-MID CAP CONFERENCE PRESENTATION March 2021 Discover Develop Dr Graham Kelly CEO and Managing Director Deliver NOXOPHARM LIMITED (ASX:NOX) 1
Slide 4: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not Although the Company believes that the expectations reflected in the forward looking statements be considered as an offer or invitation to subscribe for, or purchase any shar
Slide 5: For personal use only
For personal use only Medical advances have helped delay the progression of many forms of cancer. However, once an aggressive cancer becomes metastatic (with secondary tumours), current treatment options generally are very limited in their effectiveness Our aim is simple. To boost the effectiveness
Slide 6: Veyonda breakthrough COLD to HOT immunotherapy drug
Veyonda® breakthrough COLD to HOT For personal use only immunotherapy drug Blocks autophagy Activates immune abscopal cells responses Inhibits Increases inflammaBon trafficking of activated immune cells Source: Dana-Faber Cancer InsPtute Converts COLD tumors to HOT tumors NOXOPHARM LIMITED (ASX:NOX)
Slide 7: Treatment options for metastatic cancer
Treatment options for metastatic cancer For personal use only Used in most cancers Limited to certain cancer types Radiotherapy Immunotherapy RadiopharmaceuPcals Chemotherapy Targeted therapies NOXOPHARM LIMITED (ASX:NOX) 5
Slide 8: Proof-of-concept being sought by NOX in different cancer treatments
Proof-of-concept being sought by NOX in 3 different cancer treatments For personal use only DARRT IONIC Immunotherapy Radiotherapy Radiopharmaceuticals LuPIN Chemotherapy Targeted therapies NOXOPHARM LIMITED (ASX:NOX) 6
Slide 9: DARRT: Veyonda + Low Dose Radiotherapy
For personal use only DARRT Veyonda® + Low Dose Radiotherapy A revolutionary new treatment for solid cancer NOXOPHARM LIMITED (ASX:NOX) 7
Slide 10: DARRT Program: Veyonda + Low-Dose Radiotherapy
DARRT Program For personal use only Veyonda® + Low-Dose Radiotherapy 🔴 In metastaIc cancer, radiotherapy (RT) generally applied to 1 or 2 individual tumours 🔴 Mainly used for relief of symptoms (eg pain, loss of funcIon) 🔴 No meaningful effect on paIent survival or disease progression expected…
Slide 11: DARRT Program: Direct and Abscopal Response to Radiotherapy
DARRT Program Direct and Abscopal Response to Radiotherapy For personal use only 🔴 Aim is to deliver a dose of radiation to a single tumour and to shrink or eradicate that tumour 🔴 In the overwhelming majority of cases, the effect of the radiation is restricted to the irradiated tumour 🔴 In…
Slide 12: DARRT Program
DARRT Program For personal use only Low-dose radiotherapy Veyonda® (NOX66) ☛ to a single lesion ☛ 21-day cycle: daily dosing for 14 days (7 ☛ external beam radiotherapy days rest) ☛ 8-30 Gy ☛ starting Day -1 ☛ 1-10 fractionated doses ☛ repeat monthly cycles (in DARRT-2) until disease progression ☛ s
Slide 13: DARRT Program: DARRT-1 Phase 1 trial
DARRT Program DARRT Direct and Abscopal For personal use only DARRT-1 Phase Response 1 trial to Radiotherapy 🔴 In 10/15* men, tumours stopped growing or 26 men with end-stage prostate cancer • had stopped responding to reduced in size treatment • had metasta<c and progressive 🔴 10/16** had…
Slide 14: DARRT-2 Study Design
DARRT Program For personal use only DARRT-2 Study Design 🔴 Phase 1b/2a study 🔴 Differs from DARRT-1 in higher Veyonda dose and repeat cycles 🔴 MulI-naIonal 🔴 Prostate, breast, lung cancers 🔴 100-150 paIents 🔴 Abscopal responses + range of other anI-tumour responses 🔴 Commencing H2 2021…
Slide 15: LuPIN: Veyonda + 177lutetium-PSMA-617
For personal use only LuPIN Veyonda® + 177lutetium-PSMA-617 An exciting new treatment for prostate cancer NOXOPHARM LIMITED (ASX:NOX) 13
Slide 16: LuPIN Program
LuPIN Program For personal use only Lu-PSMA-617 is a radioacQve drug injected IV and designed to deliver radiaQon to every prostate cancer cell throughout the body Acquired by NovarQs in 2018 for US$6 billion Proposed new treatment for prostate cancer once the cancer has spread widely But …… 1/3rd m
Slide 17: LuPIN: Interim Data Reporting
LuPIN: Interim Data ReporIng For personal use only American Society of Clinical Oncology Genitourinary Cancers Symposium Feb 11-13 2021 ANSWER: Yes, the combinaBon of Veyonda and Lu-PSMA-617 looks to be considerably more effecBve than Lu-PSMA-617 on its own (based on published Phase 2 data1) 56 men M
Slide 18: LuPIN: Interim Survival Data
LuPIN: Interim Survival Data For personal use only Median overall survival = time when half the patients have died and half still alive Three standard lines of drug therapy once prostate 1st line 2nd line 3rd line End-stage cancer becomes metastaBc Historical data1 ~ 4.5 months 177 Lu-PSMA-617 alone
Slide 19: IONIC: Veyonda + nivolumab (Opdivo)
For personal use only IONIC Veyonda ® + nivolumab (Opdivo®) Overcoming resistance to checkpoint inhibitors NOXOPHARM LIMITED (ASX:NOX) 17
Slide 20: IONIC Study Phase I/II proof-of-concept study
IONIC Study Phase I/II proof-of-concept study For personal use only 15 patients pre-treated 15 patients not pre-treated with Opdivo but tumours with Opdivo because cancers not responsive considered to be unresponsive All other cancer types Typically 0-3% response rate • Melanoma • Lung • Kidney • Bl
Slide 21: Summary
SUMMARY For personal use only Both DARRT and LuPIN have provided clear evidence of proof-of-concept DARRT: Adding Veyonda to a low dose of radiotherapy not expected to do anything more than shrink a single tumour, led in men with end-stage prostate cancer to: • A halt to disease progression or be_er
Slide 22: Our commercial end-point for Veyonda
Our commercial end-point for Veyonda For personal use only A number of important blockbuster (>US$1 B annual sales) drugs are losing their exclusivity over coming years. This is putting pressure on big pharma to refresh revenue streams through M&A activity Programs focusing on immuno-oncology and ce
Slide 23: Key metrics
Key metrics For personal use only as at 12 March 2021 Market cap A$192m News Flow (next 6 months) • IONIC-1 and DARRT-2 start paBent recruitment Share price A$0.69 • COVID-19 clinical trial compleBon • Growing first-in-class drug pipeline Issued cap 278.9m shares • Pharmorage (subsidiary) progressing
Slide 24: For further information
For personal use only For further informa.on email: info@noxopharm.com web: www.noxopharm.com twiaer: @noxopharm Discover Develop Deliver NOXOPHARM LIMITED (ASX:NOX) 22